Schizophrenia and co-occurring substance use disorder: Reward, olfaction and clozapine

Schizophrenia Research

Volumn 155, Issue 1-3, 2014, Pages 45-51

  Mesholam Gately, Raquelle I ^a,b   Gibson, Lauren E ^c   Seidman, Larry J ^a,b   Green, Alan I ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Clozapine; Olfaction; Reward; Schizophrenia; Substance use disorder

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADDICTION; ADULT; ANHEDONIA; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; HUMAN; LEARNING DISORDER; MALE; ODOR; PILOT STUDY; PLEASURE; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; SENSORY STIMULATION; SMELLING; SOCIAL INTERACTION; SUBSTANCE ABUSE; UNPLEASANT SENSATION; COMPLICATION; DRUG EFFECTS; FEMALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; FLUPHENAZINE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; ODORS; PSYCHIATRIC STATUS RATING SCALES; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMELL; SUBSTANCE-RELATED DISORDERS;

EID: 84899486746     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.03.002     Document Type: Article

References (67)

1. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 1994, American Psychiatric Association, Washington, D.C.
2. Anderson A.K., Christoff K., Stappen I., Panitz D., Ghahremani D.G., Glover G., Gabrieli J.D., Sobel N. Dissociated neural representations of intensity and valence in human olfaction. Nat. Neurosci. 2003, 6(2):196-202.
3. Berridge K.C., Robinson T.E. Parsing reward. Trends Neurosci. 2003, 26(9):507-513.
4. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30(5):194-202.
5. Bowers M., Mazure C., Nelson J., Jatlow P. Psychotogenic drug use and neuroleptic response. Schizophr. Bull. 1990, 16(1):81-85.
6. Brown E.S., Nejtek V.A., Perantie D.C., Rajan Thomas N., Rush A.J. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J. Clin. Psychopharmacol. 2003, 23(4):384-388.
7. Brunette M.F., Noordsy D.L., Green A.I. Pharmacologic treatments for co-occurring substance use disorders in patients with schizophrenia: a research review. J. Dual Diagn. 2005, 1(2):41-55.
8. Brunette M.F., Dawson R., O'Keefe C.D., Narasimhan M., Noordsy D.L., Wojcik J., Green A.I. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J. Dual Diagn. 2011, 7(1-2):50-63.
9. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009, 35(2):383-402.
10. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50(2):71-83.
11. Chau D.T., Gulick D., Xie H., Dawson R., Green A.I. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology 2010, 58(2):351-356.
12. Choudhury E.S., Moberg P., Doty R.L. Influences of age and sex on a microencapsulated odor memory test. Chem. Senses 2003, 28(9):799-805.
13. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Erlbaum, New Jersey. second ed.
14. Crespo-Facorro B., Paradiso S., Andreasen N.C., O'Leary D.S., Watkins G.L., Ponto L.L.B., Hichwa R.D. Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. JAMA 2001, 286(4):427-435.
15. de Araujo I.E., Rolls E.T., Velazco M.I., Margot C., Cayeux I. Cognitive modulation of olfactory processing. Neuron 2005, 46(4):671-679.
16. Doop M.L., Park S. On knowing and judging smells: identification and hedonic judgment of odors in schizophrenia. Schizophr. Res. 2006, 81(2-3):317-319.
17. Doty R.L., Shaman P., Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 1984, 32(3):489-502.
18. Doty R.L., Applebaum S., Zusho H., Settle R.G. Sex differences in odor identification ability: a cross-cultural analysis. Neuropsychologia 1985, 23(5):667-672.
19. Drake R.E., Xie H., McHugo G.J., Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. 2000, 26(2):441-449.
20. Fazel S., Langstrom N., Hjern A., Grann M., Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA 2009, 301(19):2016-2023.
21. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM IV-Axis I Disorders 1996, APA Press, Washington, DC.
22. Goldstein J.M., Lewine R.R.J. Overview of sex differences in schizophrenia: where have we been and where do we go from here. Women and Schizophrenia 2000, 111-153. Cambridge University Press, Cambridge, UK. D. Castle, J. McGarth, J. Kulkarni (Eds.).
23. Gottfried J.A., Deichmann R., Winston J.S., Dolan R.J. Functional heterogeneity in human olfactory cortex: an event-related functional magnetic resonance imaging study. J. Neurosci. 2002, 15,22(24):10819-10828.
24. Gottfried J.A., O'Doherty J., Dolan R.J. Appetitive and aversive olfactory learning in humans studied using event-related functional magnetic resonance imaging. J. Neurosci. 2002, 15, 22(24):10829-10837.
25. Green A.I., Zimmet S.V., Strous R.D., Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv. Rev. Psychiatry 1999, 6(6):287-296.
26. Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr. Res. 2003, 60(1):81-85.
27. Green A.I., Chau D.T., Keung W.M., Dawson R., Mesholam R.I., Schildkraut J.J. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Res. 2004, 128(1):9-20.
28. Green A.I., Noordsy D.L., Brunette M.F., O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J. Subst. Abus. Treat. 2008, 34(1):61-71.
29. Guy W.B.R. CGI: Clinical Global Impressions 1976, National Institute of Mental Health.
30. Hoff R.A., Rosenheck R.A. The cost of treating substance abuse patients with and without comorbid psychiatric disorders. Psychiatr. Serv. 1999, 50(10):1309-1315.
31. Hudry J., Saoud M., D'Amato T., Dalery J., Royet J.P. Ratings of different olfactory judgements in schizophrenia. Chem. Senses 2002, 27(5):407-416.
32. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., Knutson B., Kienast T., Gallinat J., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 2007, 187(2):222-228.
33. Kamath V., Moberg P., Kohler C., Gur R., Turetsky B. Odor hedonic capacity and anhedonia in schizophrenia and unaffected first-degree relatives of schizophrenia patients. Schizophr. Bull. 2013, 39(1). 10.1093/schbul/sbr050.
34. Katata K., Sakai N., Doi K., Kawamitsu H., Fujii M., Sugimura K., Nibu K. Functional MRI of regional brain responses to 'pleasant' and 'unpleasant' odors. Acta Otolaryngol. Suppl. 2009, 562:85-90.
35. Kavannagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002, 62(5):743-755.
36. Kelley A.E., Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci. 2002, 22(9):3306-3311.
37. Kirsch P., Ronshausen S., Mier D., Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenic patients. Pharmacopsychiatry 2007, 40(5):196-198.
38. Kopala L., Clark C., Hurwitz T.A. Sex differences in olfactory function in schizophrenia. Am. J. Psychiatry 1989, 146(10):1320-1322.
39. Kopala L.C., Good K., Honer W.G. Olfactory identification ability in pre- and postmenopausal women with schizophrenia. Biol. Psychiatry 1995, 38(1):57-63.
40. Marcus P., Snyder R. Reduction of comorbid substance abuse with clozapine. Am. J. Psychiatry 1995, 152(6):959.
41. Meehl P.E. Nuisance variables and the ex post facto design. Minnesota Studies in Philosophy of Science 1970, Vol. 4:373-402. University of Minnesota Press, Minneapolis, MN.
42. Moberg P.J., Turetsky B.I. Scent of a disorder: olfactory functioning in schizophrenia. Curr. Psychiatry Rep. 2003, 5(4):311-319.
43. Moberg P.J., Agrin R., Gur R.E., Gur R.C., Turetsky B.I., Doty R.L. Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Neuropsychopharmacology 1999, 21(3):325-340.
44. Moberg P.J., Arnold S.E., Doty R.L., Kohler C., Kanes S., Seigel S., Gur R.E., Turetsky B.I. Impairment of odor hedonics in men with schizophrenia. Am. J. Psychiatry 2003, 160(10):1784-1789.
45. Moberg P.J., Kamath V., Marchetto D.M., Calkins M.E., Doty R.L., Hahn C.G., Borgmann-Winter K.E., Kohler C.G., Gur R.E., Turetsky B.I. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis. Schizophr. Bull. 2014, 40(1):50-59.
46. Murray G.K., Corlett P.R., Clark L., Pessiglione M., Blackwell A.D., Honey G., Jones P.B., Bullmore E.T., Robbins T.W., Fletcher P.C. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol. Psychiatry 2008, 13(3):239, 267-239, 276.
47. Murthy P., Chand P. Treatment of dual diagnosis disorders. Curr. Opin. Psychiatry 2012, 25(3):194-200.
48. Nisell M., Nomikos G.G., Svensson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol. Toxicol. 1995, 76(3):157-162.
49. Owen R., Fischer E., Booth B., Cuffel B. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr. Serv. 1996, 47(8):853-858.
50. Plailly J., d'Amato T., Saoud M., Royet J.P. Left temporo-limbic and orbital dysfunction in schizophrenia during odor familiarity and hedonicity judgments. Neuroimage 2006, 29(1):302-313.
51. Potvin S., Stip E., Roy J.Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int. Clin. Psychopharmacol. 2003, 18(3):121-132.
52. Potvin S., Stip E., Lipp O., Roy M.A., Demers M.F., Bouchard R.H., Gendron A. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am. J. Drug Alcohol Abuse 2008, 34(1):75-82.
53. Qureshy A., Kawashima R., Imran M.B., Sugiura M., Goto R., Okada K., Inoue K., Itoh M., Schormann T., Zilles K., Fukuda H. Functional mapping of human brain in olfactory processing: a PET study. J. Neurophysiol. 2000, 84(3):1656-1666.
54. Rolls E.T., Kringelbach M.L., de Araujo I.E. Different representations of pleasant and unpleasant odours in the human brain. Eur. J. Neurosci. 2003, 18(3):695-703.
55. Roth R.M., Brunette M.F., Green A.I. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?. Curr. Psychiatry Rep. 2005, 7(4):283-291.
56. Royet J.P., Plailly J., Delon-Martin C., Kareken D.A., Segebarth C. fMRI of emotional responses to odors: influence of hedonic valence and judgment, handedness, and gender. Neuroimage 2003, 20(2):713-728.
57. Rupp C.I., Fleischhacker W.W., Kemmler G., Kremser C., Bilder R.M., Mechtcheriakova S., Szeszkod P.R., Walcha T., Scholtze A.W., Klimbachera M., Maiera C., Albrechta G., Lechner-Schonera T., Felberb S., Hinterhuber H. Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr. Res. 2005, 74:149-161.
58. Schlagenhauf F., Juckel G., Koslowski M., Kahnt T., Knutson B., Dembler T., Kienast T., Gallinat J., Wrase J., Heinz A. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology 2008, 196(4):673-684.
59. Schultz W. Multiple reward signals in the brain. Nat. Rev. Neurosci. 2000, 1(3):199-207.
60. Seidman L.J., Goldstein J.M., Goodman J.M., Koren D., Turner W.M., Faraone S.V., Tsuang M.T. Sex differences in olfactory identification and Wisconsin Card Sorting performance in schizophrenia: Relationship to attention and verbal ability. Biol. Psychiatry 1997, 42(2):104-115.
61. Science of olfaction 1992, Springer-Verlag, New York, NY. M.J. Serby, K.L. Chobor (Eds.).
62. Sorbara F., Liraud F., Assens F., Abalan F., Verdoux H. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur. Psychiatry 2003, 18(3):133-136.
63. Strauss G.P., Allen D.N., Ross S.A., Duke L.A., Schwartz J. Olfactory hedonic judgment in patients with deficit syndrome schizophrenia. Schizophr. Bull. 2010, 36(4):860-868.
64. Ventura J., Green M., Shaner A., Liberman R.P. Training and quality assurance on the BPRS: 'The Drift Busters'. Int. J. Methods Psychiatr. Res. 1993, 3(4):221-244.
65. Wilkinson G. The Wide Range Achievement Test: Revision 3: Administration Manual 1993, Jastak Assoc, Wilmington, DE.
66. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron 2002, 36(2):229-240.
67. Zimmet S., Strous R., Burgess E., Kohnstamm S., Green A. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J. Clin. Psychopharmacol. 2000, 20(1):94-98.